Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Yohimbine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 9/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 8/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 6/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 1.00 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 1.00 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.98 |
| ▸ | TOP1 known ✓ | P11387 | 2/20 | 0.98 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.98 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.98 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rauwolscine SCHEMBL29473871 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL4654130 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL29353997 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Yohimbine SCHEMBL8084613 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL6515647 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL4463142 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL178033 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Corynantheine SCHEMBL178026 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Rauwolscine SCHEMBL21433114 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B | |
| Yohimbine SCHEMBL29354301 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AADRA2CADRA2BADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724125-A1 | APPARATUS, METHODS, AND SYSTEMS FOR ATOMIZED DELIVERY OF A COMPOSITION TO A PATIENT | Microneb Tech Holdings, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2025010709-A1 | USE OF YOHIMBINE DRUG IN TREATMENT OF TYPE 2 DIABETES | 中国科学院深圳先进技术研究院 | 2025-01-16 | — | — | WO | claimed |
| US-20250001100-A1 | LIQUID PREPARATION AND PREPARATION METHOD THEREFOR, AEROSOL GENERATION SYSTEM, CARTRIDGE FOR AEROSOL GENERATION SYSTEM, AND AEROSOL GENERATION APPARATUS | SHENZHEN FIRST UNION TECHNOLOGY CO., LTD. (CN) | 2025-01-02 | — | — | US | claimed |
| WO-2024254545-A1 | APPARATUS, METHODS, AND SYSTEMS FOR ATOMIZED DELIVERY OF A COMPOSITION TO A PATIENT | MICRONEB TECH HOLDINGS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240408210-A1 | Topical Compositions and Methods for Making and Using the Same | NOOR BRANDS COMPANY LLC (US) | 2024-12-12 | — | — | US | claimed |
| US-20240226092-A1 | APPARATUS, METHODS, AND SYSTEMS FOR PROVIDING PHARMACEUTICAL COMPOSITIONS AND ADMINISTERING MEDICATIONS TO PATIENTS | MICRONEB TECH HOLDINGS, INC. | 2024-07-11 | — | — | US | claimed |
| EP-4393481-A1 | LIQUID PREPARATION AND PREPARATION METHOD THEREFOR, AEROSOL GENERATION SYSTEM, CARTRIDGE FOR AEROSOL GENERATION SYSTEM, AND AEROSOL GENERATION APPARATUS | Shenzhen First Union Technology Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| CN-118028229-B | Preparation method for obtaining mesenchymal stem cells from nerve organoids | 成都云测医学生物技术有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118169271-A | Method for detecting alpha-adrenergic receptor blocker, SSRI and 5-ARIs and application thereof | 巴中市产品质量检验检测中心 | 2024-06-11 | — | — | CN | claimed |
| CN-118028229-A | Preparation method for obtaining mesenchymal stem cells from nerve organoids | 成都云测医学生物技术有限公司 | 2024-05-14 | — | — | CN | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-6086884-A | USING A MIXTURE OF STURGEN ROE AND YOHIMBINE FOR IMPOTENCE | OMAR LOTFI ISMAIL (US) | 2000-07-11 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5082665-A | Anti-snoring formulations using yohimbine | Verny, Tom (CA) | 1992-01-21 | — | — | US | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |
| EP-0105361-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1984-04-18 | — | — | EP | claimed |
| WO-1983003541-A1 | ANTAGONISM OF CENTRAL NERVOUS SYSTEM DRUGS BY THE ADMINISTRATION OF 4-AMINOPYRIDINE ALONE OR IN COMBINATION WITH OTHER DRUGS | UNIV GEORGIA RES FOUND (US) | 1983-10-27 | — | — | WO | claimed |